Lexaria Bioscience (LEXX) said Tuesday that an oral form of tirzepatide processed through its DehydraTECH drug delivery platform caused 47% fewer adverse events than Eli Lilly's (LLY) injectable Zepbound.
The company said partial final results of its study comparing the two versions showed that the oral DehydraTECH-tirzepatide version produced 20 adverse events compared with the injection's 38 adverse events.
Both versions produced "similarly increased levels of insulin from baseline" at the end of the eight-day study of nine participants, while blood glucose reductions from each version were comparable, Lexaria Bioscience added.
Additional results from the study are still undergoing analysis and the company said it plans to add a fifth arm to evaluate DehydraTECH-tirzepatide in an oral capsule.
Shares of Lexaria Bioscience were down more than 11% in early Tuesday trading.
Price: 1.87, Change: -0.19, Percent Change: -9.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.